Bristol Myers Squibb reported $49.2B of revenue over the trailing twelve months, +3.1% on the year before. 11 reported series are charted on this page, each one as filed. Revenue, trailing twelve months: $49.2B (to Q2 2026). Net income: $9.28B, trailing twelve months to Q2 2026. Free cash flow: $11.4B, trailing twelve months to Q2 2026. Operating margin: 24%, trailing twelve months to Q2 2026.

BMYBristol Myers Squibb

Healthcare

$59.11+34% 1Y

$59.11

$41.6752 weeks$68.08

BMY as reported

Bristol Myers Squibb reported $49.2B of revenue over the trailing twelve months, +3.1% on the year before. 11 reported series are charted on this page, each one as filed.

$49.2B

Revenue, trailing twelve months · to Q2 2026 · +3.1% against the twelve months before

Net income: $9.28B
Net income · +84% year on year · trailing twelve months to Q2 2026
Free cash flow: $11.4B
Free cash flow · −22% year on year · trailing twelve months to Q2 2026
Operating margin: 24%
Operating margin · trailing twelve months to Q2 2026

Details›

Every series Ryufin has for BMY, trailing twelve months
Series	Latest	Year on year	As of
Revenue	$49.2B	+3.1%	Q2 2026
Net income	$9.28B	+84%	Q2 2026
EPS	$4.54	+83%	Q2 2026
Gross margin	70%	n/a	Q2 2026
Operating margin	24%	n/a	Q2 2026
Net margin	19%	n/a	Q2 2026
ROE	37%	n/a	Q2 2026
ROA	8.3%	n/a	Q2 2026
ROIC	14%	n/a	Q2 2026
Free cash flow	$11.4B	−22%	Q2 2026
P/E	13.0	n/a	today

Every figure straight from the statements filed with the SEC, no scoring. Per-share figures and share counts are restated for stock splits, so a split never shows up as a collapse. Open a series for its full history.